Clinical Trials
19
Active:12
Completed:1
Trial Phases
2 Phases
Phase 1:12
Phase 2:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 1
12 (63.2%)Phase 2
7 (36.8%)A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Phase 2
Active, not recruiting
- Conditions
- Achondroplasia
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 22
- Registration Number
- NCT06433557
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, London, United Kingdom
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Phase 2
Recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for Navepegritide
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 72
- Registration Number
- NCT06079398
- Locations
- 🇬🇧
Ascendis Investigational Site, London, United Kingdom
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 140
- Registration Number
- NCT05929807
- Locations
- 🇮🇪
Ascendis Pharma Investigational Site, Dublin, Ireland
🇵🇹Ascendis Investigational Site, Coimbra, Portugal
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Phase 2
Active, not recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 84
- Registration Number
- NCT05598320
- Locations
- 🇪🇸
Ascendis Pharma Investigational Site, Vitoria, Spain
News
No news found